Letter
Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted
-
* Corresponding author: Darren M Roberts dmroberts@iprimus.com.au
Critical Care 2007, 11:413 doi:10.1186/cc5786
No comments have yet been made on this article.